Ronald A DePinho
Overview
Explore the profile of Ronald A DePinho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
45914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de la Iglesia N, Konopka G, Puram S, Chan J, Bachoo R, You M, et al.
Genes Dev
. 2025 Feb;
39(3-4):299.
PMID: 39900475
No abstract available.
2.
Wong K, Maser R, Bachoo R, Menon J, Carrasco D, Gu Y, et al.
Nature
. 2025 Jan;
638(8050):E7.
PMID: 39849018
No abstract available.
3.
Bachoo R, Maher E, Ligon K, Sharpless N, Chan S, You M, et al.
Cancer Cell
. 2024 Dec;
42(12):2124.
PMID: 39663072
No abstract available.
4.
Ying H, Kimmelman A, Bardeesy N, Kalluri R, Maitra A, DePinho R
Genes Dev
. 2024 Nov;
39(1-2):36-63.
PMID: 39510840
Pancreatic ductal adenocarcinoma (PDAC) poses a grim prognosis for patients. Recent multidisciplinary research efforts have provided critical insights into its genetics and tumor biology, creating the foundation for rational development...
5.
Saito Y, Xiao Y, Yao J, Li Y, Liu W, Yuzhalin A, et al.
Cell Discov
. 2024 Oct;
10(1):109.
PMID: 39468013
Advanced pancreatic ductal adenocarcinomas (PDACs) respond poorly to all therapies, including the first-line treatment, chemotherapy, the latest immunotherapies, and KRAS-targeting therapies. Despite an enormous effort to improve therapeutic efficacy in...
6.
Liu Y, Han J, Hsu W, LaBella K, Deng P, Shang X, et al.
Cancer Discov
. 2024 Sep;
15(1):162-178.
PMID: 39348506
Clinically available KRAS* inhibitors and IO agents alleviated the immunosuppressive tumor microenvironment in PDAC. Profound tumor regression and prolonged survival in an autochthonous PDAC model provide a compelling rationale for...
7.
Takeda M, Theardy M, Sorokin A, Coker O, Kanikarla P, Chen S, et al.
bioRxiv
. 2024 Aug;
PMID: 39211217
The therapeutic benefit of recently developed mutant KRAS (mKRAS) inhibitors has been limited by the rapid onset of resistance. Here, we aimed to delineate the mechanisms underlying acquired resistance to...
8.
Shim H, Iaconelli J, Shang X, Li J, Lan Z, Jiang S, et al.
Cell
. 2024 Jun;
187(15):4030-4042.e13.
PMID: 38908367
Insufficient telomerase activity, stemming from low telomerase reverse transcriptase (TERT) gene transcription, contributes to telomere dysfunction and aging pathologies. Besides its traditional function in telomere synthesis, TERT acts as a...
9.
LaBella K, Hsu W, Li J, Qi Y, Liu Y, Liu J, et al.
Dev Cell
. 2024 Apr;
59(11):1475-1486.e5.
PMID: 38574731
Telomere dynamics are linked to aging hallmarks, and age-associated telomere loss fuels the development of epithelial cancers. In Apc-mutant mice, the onset of DNA damage associated with telomere dysfunction has...
10.
Bae S, Ling H, Chen Y, Chen H, Kumar D, Zhang J, et al.
bioRxiv
. 2023 Nov;
PMID: 38014033
Long term survival of breast cancer patients is limited due to recurrence from metastatic dormant cancer cells. However, the mechanisms by which these dormant breast cancer cells survive and awaken...